Asston Pharmaceuticals Limited’s Board of Directors convened on September 4, 2026, approving key appointments and remuneration adjustments. The company appointed M/s Yash A. Jain & Associates as Internal Auditors and M/s Panchal S K & Associates as Statutory Auditors, subject to shareholder approval. Additionally, the board recommended increased remuneration for Managing Director Mr. Ashish Narayan Sakalkar and Whole-time Director & CEO Mrs. Saili Jayaram More, alongside approving the Board’s Report and the 7th Annual General Meeting notice.
Key Board Decisions Made
On September 4, 2026, the Board of Directors of Asston Pharmaceuticals Limited held a meeting where several important resolutions were passed. A primary decision was the appointment of M/s Yash A. Jain & Associates as the company’s Internal Auditors. Concurrently, M/s Panchal S K & Associates were appointed as the Statutory Auditors, a decision pending the approval of the company’s shareholders.
Management Remuneration and Governance
The board also addressed the remuneration of key management personnel. Proposals to increase the remuneration for Mr. Ashish Narayan Sakalkar, the Managing Director (DIN: 06601011), and Mrs. Saili Jayaram More, the Whole-time Director and CEO (DIN: 02691527), were approved, subject to shareholder consent and applicable laws. Mr. Ashish Narayan Sakalkar, who was eligible for retirement by rotation, has been recommended for re-appointment as Managing Director.
Annual General Meeting Preparations
In preparation for the upcoming corporate events, the Board approved the 7th Annual Report for the financial year ended March 31, 2026, including the Management Discussion and Analysis Report. They also appointed M/s Pragya & Associates as Scrutinizers for the 7th Annual General Meeting (AGM). The Notice for the 7th AGM was approved, along with setting September 22, 2026, as the cut-off date for e-voting. The 7th AGM itself is scheduled to be held on September 29, 2026, at 12:30 P.M. via video conferencing and other audio-visual means.
Source: BSE
